ArticlePharmaceuticals (Basel, Switzerland)2014

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets.

Philip Lammers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.